← Leaderboards
Julian G Hurdle
University Of Texas Arlington
$9,268,678
Attributed
$10,998,888
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,460,346 · 8
By mechanism
R01$9,485,696 · 3
R21$1,367,096 · 4
R56$607,554 · 1
Top collaborators
- Kirk Edward Hevener6 shared
- Kevin W Garey5 shared
- Sasanka S Chukkapalli4 shared
- Kelli Lea Palmer2 shared
Others in their field
Top investigators on “Clostridium Difficile”
- Urs Ochsner · Crestone, Inc.$20,004,167
- Hanping Feng · University Of Maryland Baltimore$18,578,582
- Nasia Safdar · Wm S. Middleton Memorial Veterans Hosp$14,163,407
- William A Petri · University Of Virginia$13,916,669
- Vincent B Young · Michigan State University$12,048,959
- Robert A Britton · Baylor College Of Medicine$11,320,245
Research focus
Clostridium DifficileMetronidazoleInfectionAntibioticsOrganismAffectIn VitroGeneticPublic HealthPreventResistanceCessation Of LifeRecurrenceMolecularHospitalsIn VivoVancomycinMutantPathway InteractionsUnited StatesEpidemicEvolutionPharmaceutical PreparationsHealthcare
Grant awards (28)
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$744,973
R01 · FY2025 · AI · contact PI
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$191,250
R21 · FY2025 · DE · contact PI
ConProject-001$27,583
R21 · FY2025 · DE · contact PI
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$27,583
R21 · FY2025 · DE · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$768,082
R01 · FY2024 · AI · contact PI
Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium$242,625
R21 · FY2024 · DE · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$183,766
R01 · FY2024 · AI · contact PI
Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$52,374
R01 · FY2024 · AI · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.$796,393
R01 · FY2023 · AI · contact PI
Mechanism Of Enterococcus Faecalis Nitro Drug Metabolism And In Vivo Implications$232,000
R21 · FY2023 · AI
High Throughput Screening for Non-antibiotic inhibitors of Clostridium difficile Pathophysiology$502,575
R01 · FY2022 · AI · contact PI
Mechanism Of Enterococcus Faecalis Nitro Drug Metabolism And In Vivo Implications$222,000
R21 · FY2022 · AI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$675,085
R01 · FY2021 · AI · contact PI
High Throughput Screening for Non-antibiotic inhibitors of Clostridium difficile Pathophysiology$538,467
R01 · FY2021 · AI · contact PI
High Throughput Screening for Non-antibiotic inhibitors of Clostridium difficile Pathophysiology$736,192
R01 · FY2020 · AI · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$654,080
R01 · FY2020 · AI · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$696,716
R01 · FY2019 · AI · contact PI
High Throughput Screening for Non-antibiotic inhibitors of Clostridium difficile Pathophysiology$577,822
R01 · FY2019 · AI · contact PI
Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection$647,212
R01 · FY2018 · AI · contact PI
Relationships Among Metronidazole Resistance, Pharmacodynamics and Treatment Outcomes in Clostridium difficile Infection$607,554
R56 · FY2017 · AI · contact PI
Investigation of the FAS-II enzyme, FabK, as a druggable target for C. difficile$232,158
R21 · FY2017 · AI
Investigation of the FAS-II enzyme, FabK, as a druggable target for C. difficile$191,897
R21 · FY2016 · AI
Nature inspired treatments for persistent C. difficile infections$372,578
R01 · FY2015 · AT · contact PI
Nature inspired treatments for persistent C. difficile infections$234,288
R01 · FY2014 · AT · contact PI
Nature inspired treatments for persistent C. difficile infections$142,455
R01 · FY2014 · AT · contact PI
Nature inspired treatments for persistent C. difficile infections$376,799
R01 · FY2013 · AT · contact PI
Nature inspired treatments for persistent C. difficile infections$388,143
R01 · FY2012 · AT · contact PI
Nature inspired treatments for persistent C. difficile infections$397,696
R01 · FY2011 · AT · contact PI